2-azaniumylethyl [1-hexadecanoyloxy-3-[(Z)-octadec-9-enoyl]oxypropan-2-yl] phosphate | 884324-34-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: 2-azaniumylethyl [1-hexadecanoyloxy-3-[(Z)-octadec-9-enoyl]oxypropan-2-yl] phosphate
• CAS: 884324-34-9
• 化学式: C39H76NO8P
• 分子量: 718.0
• InChiKey: BLMYNJDXEOSYBR-ZCXUNETKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.4
• 重原子数：
  49
• 可旋转键数：
  40
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  134
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• An adjuvant system comprising virosomes and liposomes
  申请人：Pevion Biotech Ltd.

  公开号：EP1797895A1

  公开（公告）日：2007-06-20

  The invention relates to novel adjuvant systems that generate efficient immune responses against antigens of choice. The novel adjuvant systems of the present invention are based on virosomes. Thus the invention is directed to immunogenic compositions comprising virosomes, at least one antigenic molecule, and a carrier vehicle, methods for preparing such compositions and uses thereof.

  本发明涉及新型佐剂系统，它能产生针对所选抗原的高效免疫反应。本发明的新型佐剂系统以病毒体为基础。因此，本发明涉及由病毒体、至少一种抗原分子和载体载体组成的免疫原性组合物、制备这种组合物的方法及其用途。
• Non-specific immunostimulating agents
  申请人：Pevion Biotech AG

  公开号：EP1938835A1

  公开（公告）日：2008-07-02

  The present invention relates to a lipid vesicle. The invention further relates to the use of such a lipid vesicle for the preparation of a medicament. The invention further relates to a method of treating and/or preventing a disease or disorder involving administering such a lipid vesicle to an animal in need thereof.

  本发明涉及一种脂质囊泡。本发明还涉及使用这种脂质囊泡制备药物。本发明还涉及一种治疗和/或预防疾病或失调的方法，包括向需要的动物施用这种脂质囊泡。
• Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof
  申请人：Pevion Biotech AG

  公开号：EP2014279A1

  公开（公告）日：2009-01-14

  The present invention relates to virosomes comprising hemagglutinin (HA) with improved fusion activity. Preferably, the HA comprised in said virosomes was derived from influenza virus produced in a cell line. The present invention also relates to compositions and a kit comprising the virosomes according to the invention. Further, the present invention relates to uses and methods involving said virosomes, as well as to a method for preparing same.

  本发明涉及由具有更好融合活性的血凝素（HA）组成的病毒体。优选地，所述病毒体中包含的 HA 来自细胞系中产生的流感病毒。本发明还涉及包含本发明所述病毒体的组合物和试剂盒。此外，本发明还涉及上述病毒体的用途和方法，以及制备上述病毒体的方法。
• Truncated secretory aspartyl proteinase 2
  申请人：Pevion Biotech AG

  公开号：EP2039764A1

  公开（公告）日：2009-03-25

  The present invention relates to a truncated form of the secretory aspartyl proteinase 2 (Sap2), as well as to nucleic acid molecules encoding same. This truncated Sap2 polypeptide (tSap2) is surprisingly stable and devoid of enzymatic activity but retains full immunogenicity upon intravaginal administration and confers full protection against intravaginal challenge by the Candida fungus. The present invention further relates to compositions comprising tSap2 and to the use of tSap2 in the preparation of such compositions.

  本发明涉及一种截短形式的分泌型天冬氨酰蛋白酶 2（Sap2）以及编码这种蛋白酶的核酸分子。这种截短的 Sap2 多肽（tSap2）出人意料地稳定且没有酶活性，但在阴道内给药时仍具有完全的免疫原性，并能完全抵御念珠菌在阴道内的挑战。本发明进一步涉及包含 tSap2 的组合物以及 tSap2 在制备此类组合物中的用途。
• Multiepitope vaccine for Her2/neu-associated cancers
  申请人：Pevion Biotech Ltd.

  公开号：EP2292258A1

  公开（公告）日：2011-03-09

  The present invention relates to fusion peptides comprising fragments of the cancer-related protein Her2/neu, methods of preparing such fusion peptides, delivery systems associated with such fusion peptides, compositions comprising such fusion peptides and/or delivery systems, and medical uses of such fusion peptides, delivery systems and/or compositions for the prevention, treatment and/or amelioration of a cancer associated with expression or over-expression of the Her2/neu protein.

  本发明涉及包含癌症相关蛋白Her2/neu片段的融合肽、制备此类融合肽的方法、与此类融合肽相关的递送系统、包含此类融合肽和/或递送系统的组合物，以及此类融合肽、递送系统和/或组合物在预防、治疗和/或改善与Her2/neu蛋白表达或过度表达相关的癌症方面的医学用途。